trending Market Intelligence /marketintelligence/en/news-insights/trending/yuWzvMmXeYRPEp__-yta9w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Novo Nordisk blockbuster diabetes drug Ozempic wins FDA nod for expanded use

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Novo Nordisk blockbuster diabetes drug Ozempic wins FDA nod for expanded use

Novo Nordisk A/S said the U.S. Food and Drug Administration approved a label expansion for the company's blockbuster diabetes drug Ozempic.

The U.S. regulator granted the label expansion to the injectable drug for reducing the risk of major adverse cardiovascular events — including cardiovascular death, nonfatal heart attack or nonfatal stroke — in adults with type 2 diabetes and established cardiovascular disease.

The approval was supported by results of a phase 3 trial called Sustain 6, in which Ozempic reduced the risk of major adverse heart events by 21% compared to placebo, according to a Jan. 16 news release.

The U.S. FDA first approved Ozempic in 2017 to improve glycemic control in adults with type 2 diabetes. Ozempic is also approved in the EU and Japan, among other territories.

SNL Image